USA - NASDAQ:ATHE - US02155X2053 - ADR
Overall ATHE gets a fundamental rating of 4 out of 10. We evaluated ATHE against 538 industry peers in the Biotechnology industry. ATHE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATHE is valued quite expensively, but it does show have an excellent growth rating.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -26.39% | ||
ROE | -28.65% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 9.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 12.98 | ||
Quick Ratio | 12.98 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:ATHE (9/24/2025, 11:39:02 AM)
4.43
-0.03 (-0.67%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 222.46 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.34 | ||
P/tB | 2.34 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -26.39% | ||
ROE | -28.65% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | 0% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 12.98 | ||
Quick Ratio | 12.98 | ||
Altman-Z | 9.94 |